stockportfolio.pro
Stocks / AXSM vs EXEL
AXSM vs EXEL
Axsome Therapeutics, Inc. and Exelixis, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
EXEL is the larger company ($13.4B vs $13.0B). On the fundamentals, EXEL earns a higher net margin (33.7% vs -28.7%); EXEL has the stronger return on equity (36.2% vs -207.5%). Full numbers below — the stronger figure on each row is in green.
| Axsome Therapeutics, Inc. (AXSM) | Exelixis, Inc. (EXEL) | |
|---|---|---|
| Market cap | $13.0B | $13.4B |
| Revenue (latest FY) | $638.50M | $2.32B |
| Net income (latest FY) | $-183.17M | $782.57M |
| Revenue growth (5y CAGR) | — | 18.6% |
| Net margin | -28.7% | 33.7% |
| Return on equity | -207.5% | 36.2% |
| P/E ratio | — | 17.6 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 9 |
| Positive free cash flow | No | Yes |
Compare with another company:
See the full AXSM vs EXEL breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open AXSM's full financials → Open EXEL's full financials →More comparisons
Frequently asked questions
Which is bigger, AXSM or EXEL?
Exelixis, Inc. is larger by market capitalization — $13.4B versus $13.0B.
Which grows faster, AXSM or EXEL?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.